mb07811
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00879112)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
THRB agonist
Ph2 study withdrawn. Prodrug of MB07344.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc(Cc2c(C)cc(OC[P@@]3(=O)OCC[C@H](O3)c4cccc(Cl)c4)cc2C)ccc1O- Mol. weight
- 514.99 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL471897 ↗
- ChEMBLCHEMBL457748 ↗
Also known as
- 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane
- mb07811
- mb07811
- mb07811
- mb07811
- mb07811
- mb 07811
- mb-07811
- mb-07811
- mb-07811
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00879112 | Phase 2 | Apr 1, 2009 | Ligand Pharmaceuticals, Metabasis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | For profit | 1 | 1 | 1 | 2009 |
| Metabasis | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1